摘要
目的 :观察LipoPGE1(凯时 )注射液对糖尿病周围神经病变及糖尿病肾病患者血浆内皮素 1(ET 1)及尿蛋白的影响。方法 :选取糖尿病周围神经病变患者 85例 ,随机分为常规治疗组 4 2例及凯时治疗组 4 3例 ,治疗3周 ,测定治疗前后ET 1,2 4h尿微量白蛋白排泄率 (2 4hUAE) ,N 乙酰 β D 氨基葡萄糖苷酶 (NAG)及周围神经传导速度的变化 ,并选择 2 0名同年龄段健康人为正常对照组。结果 :患者治疗前周围神经传导速度明显低于健康人 ,治疗后明显增加 ;ET 1、2 4hUAE、NAG水平明显高于正常健康人 ,治疗后明显降低 ,并且ET 1和尿蛋白间存在相关性。结论 :糖尿病周围神经病变及肾病的发生发展与ET 1有关。凯时可降低血浆ET 1水平 ,改善糖尿病周围神经病变症状及 2
Objective:To study the effect of Lipo-PGE1 injection in treating diabetic neuropathy and nephropathy.Methods:85 cases were randomly divided into two groups, 42 cases in the control group, and 43 cases in the Lipo-PGE 1 treated group,consecutive treated for 3 weeks.Levels of plasma endothelin-1(ET-1),24 hours urinary trace albumin excretion rate (24hUAE) N-acetyl-β-D-glucosaminidase(NAG)and nerve conduction velocity were measured respectively.Moreover,the above indexes in 20 healthy subjects were also measured as a control.Results:The levels of plasma ET-1,24hUAE, NAG were higher,but nerve conduction velocity was lower than those in healthy subjects.After treatment of Lipo-PGE1,the levels of plasma ET-1,24hUAE and NAG decreased significantly,and nerve conduction velocity increased significantly. It was found that the level of 24hUAE was closely associated with ET-1.Conclusion:These findings suggested that increased ET-1 concentrations assist development and progression of diabetic nephropathy and neuropathy, and Lipo-PGE1 is effective for inhibition of diabetic nephropathy and neuropathy mediated by reduction of ET-1 concentrations.
出处
《中日友好医院学报》
2004年第4期223-225,共3页
Journal of China-Japan Friendship Hospital
关键词
LIPO-PGE1
糖尿病周围神经病变
糖尿病肾病
治疗
Lipo-PGE 1
Diabetic Nephropathy
Diabetic Neuropathy Author′s Address Department of International Medical,China-Japan Friendship Hospital,Beijing,100029,China
